LINGAIN
OFFICIAL TITLE: PROSPECTIVE EVALUATION OF PREDICTIVE/PROGNOSTIC IMMUNOGENICITY BIOMARKERS FOR TARGET THERAPY IN HER2-POSITIVE EARLY BREAST CANCER WITHIN THE PHERGAIN CLINICAL STUDY.
STUDY DETAILS
THE LINGAIN PROJECT, AS A SUBSTUDY OF THE PHERGAIN TRIAL, HAS THE POTENTIAL INTEREST TO IDENTIFY IMMUNOGENICITY BIOMARKERS OF RESPONSE OR RESISTANCE LINKED TO TARGETED ANTI-HER2 THERAPY. IN THIS EXPLORATORY AND COMPREHENSIVE STUDY, WE HYPOTHESIZE THAT THE ACTIVATION OF THE DIFFERENT SUBTYPES OF ΓΔ T CELLS IN PERIPHERAL BLOOD DURING DUAL HER2 BLOCKADE WITH TRASTUZUMAB AND PERTUZUMAB IS A SIGNAL OF IMMUNE RESPONSE, AND IT COULD BE CONSIDERED AN EARLY MARKER USEFUL TO PREDICT THE EFFICACY OF BIOLOGICAL THERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
HER2+ EBC
Sub-study
42
10
Spain
Closing